Alternatives to Oral Valacyclovir for Herpes Treatment

First-Line Alternatives

The Centers for Disease Control and Prevention recommends famciclovir as an effective oral alternative with a dosage of 125 mg twice daily for 5 days for episodic treatment, and 250 mg twice daily for suppressive therapy 3, 4, 5
The Centers for Disease Control and Prevention suggests oral acyclovir as an alternative with a dosage of 400 mg three times daily for 5 days, or 200 mg five times daily for 5 days, or 800 mg twice daily for 5 days for episodic treatment, and 400 mg twice daily for suppressive therapy 3, 4, 6

The Centers for Disease Control and Prevention notes that all acyclovir-resistant strains are also resistant to valacyclovir, and most are resistant to famciclovir 2, 7
The Centers for Disease Control and Prevention recommends foscarnet as a first-line treatment for proven or suspected acyclovir-resistant strains with a dosage of 40 mg/kg IV every 8 hours until clinical resolution 1, 2, 7
The Centers for Disease Control and Prevention suggests topical cidofovir gel 1% as an alternative for resistant cases, applied to lesions once daily for 5 consecutive days 1, 2, 7, 8

The Centers for Disease Control and Prevention recommends higher doses of oral antivirals, such as acyclovir 400 mg orally three to five times daily, and famciclovir 500 mg twice daily, until clinical resolution 2, 5
The Centers for Disease Control and Prevention suggests intravenous acyclovir 5 mg/kg every 8 hours for severe cases 2

The American Academy of Ophthalmology recommends higher doses of oral antivirals, such as oral acyclovir (400 mg five times daily), valacyclovir (500 mg three times daily), or famciclovir (250 mg twice daily) 8
The American Academy of Ophthalmology suggests considering topical antivirals as adjunctive treatment for unresponsive cases 8

The American Academy of Ophthalmology recommends evaluating patients within 1 week of treatment initiation 8
The Centers for Disease Control and Prevention suggests suspecting viral resistance if lesions persist despite adequate treatment with alternative antivirals, and considering consultation with an infectious disease specialist for resistant cases 2, 7

The Centers for Disease Control and Prevention advises against continuing ineffective therapy, and instead recommends switching to another antiviral class, such as foscarnet, for resistant cases rather than increasing valacyclovir dose 2
The Centers for Disease Control and Prevention warns against overlooking immunocompromise, as treatment failure may indicate underlying immune dysfunction requiring higher doses or IV therapy 2
The Centers for Disease Control and Prevention cautions against missing resistance, and recommends considering resistance testing and alternative treatments if lesions persist despite adequate therapy 2